Raymond James Financial Inc. Takes Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Raymond James Financial Inc. bought a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 150,967 shares of the company's stock, valued at approximately $1,159,000. Raymond James Financial Inc. owned 0.41% of iTeos Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ITOS. State Street Corp lifted its stake in iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company's stock valued at $12,000,000 after acquiring an additional 211,452 shares during the period. Peapod Lane Capital LLC purchased a new position in shares of iTeos Therapeutics during the fourth quarter worth $836,000. Readystate Asset Management LP lifted its position in iTeos Therapeutics by 97.2% during the third quarter. Readystate Asset Management LP now owns 169,819 shares of the company's stock valued at $1,734,000 after purchasing an additional 83,700 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in iTeos Therapeutics by 16.8% in the third quarter. Jacobs Levy Equity Management Inc. now owns 205,863 shares of the company's stock valued at $2,102,000 after purchasing an additional 29,549 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in iTeos Therapeutics by 3.2% in the third quarter. Geode Capital Management LLC now owns 640,350 shares of the company's stock valued at $6,540,000 after purchasing an additional 20,092 shares during the last quarter. Hedge funds and other institutional investors own 97.16% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ITOS. HC Wainwright reissued a "buy" rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a report on Thursday, March 6th. Wedbush reissued an "outperform" rating and issued a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. JPMorgan Chase & Co. dropped their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th. Finally, Wells Fargo & Company cut their target price on shares of iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, March 6th.

iTeos Therapeutics Price Performance

ITOS stock traded down $0.21 during mid-day trading on Tuesday, reaching $5.04. 327,031 shares of the company's stock were exchanged, compared to its average volume of 461,065. iTeos Therapeutics, Inc. has a 12-month low of $4.88 and a 12-month high of $18.75. The stock's 50 day moving average is $6.91 and its 200 day moving average is $7.95. The company has a market cap of $192.50 million, a price-to-earnings ratio of -1.60 and a beta of 1.43.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.13. On average, research analysts forecast that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.